Pharmaceutical promotion and transfer-pricing comparability principles limited disallowances, while uncorroborated search allegations and unsupported ...
Business expenditure substantiation supports scrap credits, statutory payments and expense claims, while depreciation requires proof of actual busines...
AAR ruled that the applicant is not entitled to input tax credit (ITC) in three key scenarios: (1) IGST paid on importing sample drugs supplied free to hospitals/clinics, (2) IGST paid by logistics service provider under Delivered Duty Paid model, and (3) CGST paid for Customs House Agent and logistics services. The ruling hinged on Section 17(5)(h) of CGST Act, which prohibits ITC for goods disposed as free samples or gifts. The sample drugs were imported for clinical trials without commercial consideration, thus categorized as free samples, rendering ITC impermissible across all associated tax payments and services.
AAR ruled that the applicant is not entitled to input tax credit (ITC) in three key scenarios: (1) IGST paid on importing sample drugs supplied free to hospitals/clinics, (2) IGST paid by logistics service provider under Delivered Duty Paid model, and (3) CGST paid for Customs House Agent and logistics services. The ruling hinged on Section 17(5)(h) of CGST Act, which prohibits ITC for goods disposed as free samples or gifts. The sample drugs were imported for clinical trials without commercial consideration, thus categorized as free samples, rendering ITC impermissible across all associated tax payments and services.
Note: It is a system-generated summary and is for quick reference only.